Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02909907
Other study ID # 15-1519
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2016
Est. completion date February 28, 2018

Study information

Verified date April 2019
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the efficacy of botulinum toxin (BoNT) injections in forearm flexors plus extensor muscles versus flexors alone for the treatment of essential hand tremor (ET).


Description:

The investigators propose a pilot, single center, double blind, randomized, parallel, placebo controlled trial comparing 2 (BoNT) injection patterns for treatment of moderate to severe essential tremor. The investigators will recruit 20 patients with (ET).


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date February 28, 2018
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age 18 and over, male or female patient with (ET) involving at least their dominant hand, as diagnosed by a movement disorders neurologist.

2. Having bothersome hand tremor in dominant hand with a hand TRS =2

3. On stable medications during last 30 days prior to enrollment.

Exclusion Criteria:

1. Presence of secondary causes of tremor, such as dystonia and parkinsonism

2. Any contraindication to botulinum toxin injections (e.g. motor neuron disease, neuromuscular junction disease, etc.)

3. History of surgical treatment for (ET).

4. Dementia as defined by DSM-V criteria

5. Patients with suboptimally treated depression and significant depressive symptoms as defined by a PHQ-9 score of =15 (PHQ-9 scores 1-4 Minimal depression; 5-9 Mild depression; 10-14 Moderate depression; 15-19 Moderately severe depression; 20-27 Severe depression). Antidepressant medications, prescribed for depression or anxiety, will be allowed if the patient has been on a stable dose for at least 30 days.

6. Patients with suboptimally treated anxiety and significant anxiety symptoms as defined by a GAD-7 score of =15 (GAD-7 scores 0-4: minimal anxiety; 5-9: mild anxiety; 10-14: moderate anxiety; 15-21: severe anxiety). Anti-anxiety medications, prescribed for anxiety, will be allowed if the patient has been on a stable dose for at least 30 days.

7. Significant renal, hepatic, cardiac and thyroid disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Botulinum toxin
Botulinum injections into dominant upper extremity using protocol outlined above.
Other:
Placebo
Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in the 6 Week Post Injection Patient Global Impression of Improvement Scale (PGIS) Between Flexors Along and Flexors Plus Extensors Groups. 6 weeks post injection Clinician Global Impression if improvement Scale (CGIS)
Assessment of improvement graded by the patient on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.
6 weeks
Secondary Difference in Tremor Rating Scale Score (TSR)Change From Baseline to Week 6 Between Flexors Alone and Flexors Plus Extensors Groups. TRS: Tremor Rating Scale : scale composed of 6 items rated from 0-4. 0=none/normal and 4 = very severe/high level of disability. Total score is the sum of all items. Max score 24 ( maximal severity of tremor) Minimal score 0= no tremor/normal. Baseline and 6 weeks
Secondary Difference in the 6 Week Post Injection Clinician Global Impression of Improvement Scale (CGIS) Between Flexors Along and Flexors Plus Extensors Groups. 6 weeks post injection Clinician Global Impression if improvement Scale (CGIS)
Assessment of improvement graded by clinician on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.
6 weeks
Secondary Difference of the Quality of Life in Essential Tremor Questionnaire (QUEST) Summary Index Change at Week 6 Compared to Baseline Between Wrist Flexors Versus Wrist Flexors Plus Extensors Group. QUEST( Quality of Life in Essential Tremor Questionnaire ) is a 30-item, ET-specific quality of life scale . Items contribute to five dimensions. Physical/ADL (9 items ), Psychosocial (9 items), Communication (3 items), Hobbies/Leisure (3 items), and Work/Finances (6 items). The score on each scale is expressed as a percentage of the total score possible, with a higher score indicating greater dissatisfaction with that domain of QOL. A total or summary index corresponds to the mean of the five domain scores. The total summary index corresponds to the mean of the five domain scores. Maximal score 100: worse quality of life. Minimal Score 0: best quality of life. This outcome represents the median of the differences between baseline and week 6 in QUEST summary index.Positive index change values indicate that the score increased and negative values indicate that the score decreased. Baseline and 6 weeks
Secondary Difference in the Post Injection Grip Strength Change Between Flexor Only Group and Flexor and Extensors Group at 6 Weeks. the median of the differences in grip strength between baseline and week 6, A negative value indicates a decrease in grip strength in Kg at week 6. 6 weeks
Secondary 12 Weeks Post Injection Tremor Rating Scale for Flexors Group and Flexors Plus Extensors Group. TRS: Tremor Rating Scale : scale composed of 6 items rated from 0-4. 0=none or normal and 4 = very severe or high level of disability. Total score is the sum of all items. Max score 24 ( maximal severity of tremor) Minimal score 0= no tremor/normal. 12 weeks
Secondary 12 Week Post Injection in Clinician Global Impression Scale-Improvement Subscale (CGIS) 12 week post injection in Clinician Global Impression Scale-Improvement Subscale (CGIS)
Assessment of improvement graded by the clinician on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.
12 weeks
Secondary 12 Week Post Injection Patient Global Impression Scale-Improvement Subscale (PGIS) Patient Global Impression Scale-Improvement Subscale (PGIS)
Assessment of improvement graded by patient on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.
12 weeks
Secondary Difference of Quality of Life in Essential Tremor Questionnaire (QUEST) Summary Index Change at Week 12 Compared to Baseline Between Wrist Flexors Versus Wrist Flexors Plus Extensors Group. QUEST( Quality of Life in Essential Tremor Questionnaire ) is a 30-item, ET-specific quality of life scale . Items contribute to five dimensions. Physical/ADL (9 items ), Psychosocial (9 items), Communication (3 items), Hobbies/Leisure (3 items), and Work/Finances (6 items). The score on each scale is expressed as a percentage of the total score possible, with a higher score indicating greater dissatisfaction with that domain of QOL. A total or summary index corresponds to the mean of the five domain scores. The total summary index corresponds to the mean of the five domain scores. Maximal score 100: worse quality of life. Minimal Score 0: best quality of life. This outcome represents the median of the differences between baseline and week 6 in QUEST summary index. Positive index change values indicate that the score increased and negative values indicate that the score decreased. Baseline and 12 weeks.
See also
  Status Clinical Trial Phase
Withdrawn NCT05381688 - VIM DBS Respiratory Modulation: N-of-1 Trial
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Completed NCT02277106 - Evaluate SAGE-547 in Participants With Essential Tremor Phase 2
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A
Terminated NCT02678429 - Atlas Predicted DBS Settings in Essential Tremor N/A
Completed NCT02523807 - Tremor Monitoring Device N/A
Active, not recruiting NCT02255929 - Gamma Knife Radiosurgery for Treatment of Essential Tremor N/A
Completed NCT01223144 - Decision-making and Emotion Recognition in Essential Tremor N/A
Completed NCT00906412 - Ventrointermediate Nucleus (VIM DBS) and Working Memory N/A
Recruiting NCT05214222 - Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT03051178 - Wearable Sensor for Responsive DBS for ET N/A
Recruiting NCT03795935 - Relief From Side Effects: Clinical Use of Electrodes With Direction N/A
Not yet recruiting NCT06036368 - Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor N/A
Recruiting NCT05897775 - Coordinated Reset Deep Brain Stimulation for Essential Tremor Phase 1
Recruiting NCT05968976 - Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET N/A
Completed NCT06314139 - Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study. N/A
Recruiting NCT04501133 - Sensory-specific Peripheral Stimulation for Tremor Management N/A
Active, not recruiting NCT03560622 - Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy N/A
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A